Enfortumab Vedotin

What Enfortumab Vedotin Means in Everyday Medical Language

Enfortumab vedotin, often called Padcev, is a medicine designed to treat certain cancers of the bladder and urinary tract, known as urothelial cancers. It is a type of targeted therapy called an antibody-drug conjugate. This means it combines a special antibody that seeks out cancer cells with a chemotherapy drug that kills them. The antibody part attaches to a protein called nectin-4 found on some cancer cells. Once attached, the drug is delivered directly inside the cancer cells to help destroy them. This targeted approach aims to reduce harm to healthy cells.

Why Enfortumab Vedotin Can Matter in Cancer Care

Enfortumab vedotin offers an important treatment option for adults whose urothelial cancer has spread or cannot be removed by surgery. It is often used after other treatments, such as platinum-based chemotherapy or immunotherapy, have been tried. Because it targets cancer cells specifically, it may also help the immune system fight the cancer. This drug is not a cure but may help control cancer growth and improve symptoms. It is also being studied for other cancers, so its use might expand in the future.

What Patients Might See or Hear About Enfortumab Vedotin

Patients may hear about enfortumab vedotin during discussions of treatment plans, drug information sheets, or clinical trials. It might be mentioned as Padcev or enfortumab vedotin—both names refer to the same drug. Common side effects can include tiredness, nerve changes like tingling or numbness, rash, hair loss, nausea, and changes in taste. Because it is a newer treatment, patients might have questions about how it works, possible side effects, and how it fits with other treatments.

How Doctors Use Enfortumab Vedotin in Treatment

Doctors use enfortumab vedotin after carefully diagnosing and staging the cancer. It is chosen when surgery is not possible and when other treatments have not worked or cannot be used. It can be given alone or with pembrolizumab, an immunotherapy drug. During treatment, doctors monitor how well the cancer responds and watch for side effects. The decision to use this drug depends on the cancer’s characteristics, previous treatments, and the patient’s overall health.

Common Questions and Understanding Enfortumab Vedotin

Because enfortumab vedotin is a targeted therapy and an antibody-drug conjugate, patients may find these terms confusing. It is helpful to ask the care team how the drug works, what side effects to expect, and how it fits into the overall treatment plan. Patients should also ask about possible interactions with other medications and what monitoring will be needed during treatment. Understanding that Padcev and enfortumab vedotin are the same drug can help avoid confusion when reading medical records or drug information.

Important Safety and Next Steps

This information is meant to educate and does not replace medical advice. Each patient’s situation is unique, so treatment decisions should be made with a healthcare professional familiar with the individual’s health and cancer details. If you or a loved one is facing urothelial cancer and enfortumab vedotin is mentioned, the best next step is to ask your care team what it means for your specific case and how it fits into your treatment plan.